Active	Status	Sponsor type	Region	Phase	Filter
3 Active 10 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Infante, Jeffrey
NCT00600496: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) P1 data Mar 2012 - Mar 2012: P1 data	Active, not recruiting	1	140	US	AZD6244, ARRY-142886, Dacarbazine, Erlotinib, Docetaxel, Taxotere®, Temsirolimus	AstraZeneca	Breast Cancer, Breast Neoplasms, Colon Cancer, Colonic Cancer, Colon Neoplasms, Lung Cancer, Melanoma, Kidney Cancer	08/10	12/24
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)	Recruiting	1	475	Europe, US, RoW	TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin	GlaxoSmithKline	Neoplasms	08/25	02/27
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors Oct 2019 - Mar 2020 : From AMBER trial From AMBER trial at SITC 2018 [screenshot] Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot] From AMBER trial in combination with TSR-022 at SITC 2018 Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018	Recruiting	1	447	Europe, US, RoW	TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin	Tesaro, Inc.	Neoplasms	04/25	04/27